GLP-3 RT

GLP-3 RT (LY3437943) is a synthetic 39-amino acid peptide that acts as a triple agonist of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R).

By targeting three metabolic receptors simultaneously, GLP-3 RT represents the next evolution beyond dual-action peptides like GLP-2 TZ. The glucagon receptor component adds the potential for increased energy expenditure and fat breakdown, while GIP and GLP-1 activation address insulin secretion and appetite regulation.

In Phase II clinical trials, GLP-3 RT demonstrated substantial weight reduction, with some participants achieving over 24% body weight loss over 48 weeks. Phase III trials are currently underway.

GLP-3 RT is not approved by the FDA for any medical use. Research-grade product is sold strictly for laboratory and research purposes only.